Eli Lilly's second quarter results soundly topped Wall Street expectations on both the top and bottom lines, and the company triumphantly raised its full-year guidance midpoint by 5%.

The earnings beat was a combination of factors including slashing operating expenses and seeing big gains from key drugs like Cymbalta, which saw 22% growth for the quarter.

In this video, health care analyst David Williamson discusses the quarterly highlights, key takeaways for Eli Lilly investors, and important catalysts coming for the stock in the back half of 2013.

Follow David on Twitter: @MotleyDavid.

David Williamson owns shares of Pfizer, Zoetis and Eli Lilly. Follow David on Twitter: @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.